The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia

International Journal of Geriatric Psychiatry
C W RitchieD Ames

Abstract

Atypical antipsychotics are commonly used in the management of schizophrenia in late life with evidence suggesting they induce lower rates of motor disturbance, but have similar efficacy to conventional antipsychotics. Trials in the elderly have been either retrospective, small, of short duration or of a single-arm design. To demonstrate the effects upon motor side-effects, efficacy, safety and quality of life (QOL) of switching elderly patients with schizophrenia from conventional antipsychotics to olanzapine or risperidone. Elderly patients with schizophrenia were randomly allocated to olanzapine or risperidone and followed through an open-label crossover period. Between and within group intention to treat analyses were conducted. 66 patients were randomised (mean age 69.6 [SD +/- 6.2]). Four (11.8%) patients on olanzapine and 8 (26.7%) patients on risperidone failed to complete the crossover because of treatment failure [Odds Ratio (OR) = 2.73[0.73-10.2] p = 0.14]. The mean doses upon completion of switching in each arm were 9.9 mg (SD = 4.2) and 1.7 mg (SD = 1.2) for olanzapine and risperidone respectively. In both arms there was improvement in Parkinsonism, though only olanzapine was associated with a reduction in dyskinet...Continue Reading

References

Apr 1, 1979·The British Journal of Psychiatry : the Journal of Mental Science·S A Montgomery, M Asberg
Nov 1, 1975·Journal of Psychiatric Research·M F FolsteinP R McHugh
May 1, 1989·The British Journal of Psychiatry : the Journal of Mental Science·T R Barnes
Jan 1, 1970·Acta Psychiatrica Scandinavica. Supplementum·G M Simpson, J W Angus
Apr 1, 1982·Archives of General Psychiatry·N R Schooler, J M Kane
Sep 1, 1995·Archives of General Psychiatry·D V JesteL A McAdams
Mar 1, 1995·Harvard Review of Psychiatry·R A Sweet, B G Pollock
Sep 2, 1998·International Journal of Psychiatry in Medicine·S J KiralyS G Holliday
Nov 3, 1998·Biological Psychiatry·D A WirshingW C Wirshing
Jan 27, 1999·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·D V JesteJ Lacro
Apr 1, 2000·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·K Solomons, O Geiger
Apr 1, 1996·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Ileana BermanMiklos F Losonczy

❮ Previous
Next ❯

Citations

Oct 9, 2007·Current Opinion in Psychiatry·Jessica Broadway, Jacobo Mintzer
Nov 18, 2006·Psychiatry and Clinical Neurosciences·Shinsuke NakanishiToshihiko Takahashi
Apr 26, 2014·PloS One·Maarten BakMarjan Drukker
Jul 31, 2008·Drugs & Aging·John W Kasckow, Sidney Zisook
Jan 1, 2008·International Journal of Psychiatry in Clinical Practice·Lars HelldinTrevor Archer
Apr 2, 2013·Expert Opinion on Drug Safety·José López-SendónJusto G de Yébenes
Oct 19, 2006·Expert Opinion on Drug Safety·Maria A Mena, Justo G de Yébenes
Nov 11, 2003·Current Medical Research and Opinion·Ibrahim S Al-ZakwaniTara R Cockerham
Mar 3, 2006·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Peter FalkaiUNKNOWN WFSBP Task Force on Treatment Guidelines for Schizophrenia
Apr 1, 2011·Journal of the American Medical Directors Association·Henrike J SchoutenRob J van Marum
Dec 6, 2005·The Psychiatric Clinics of North America·Aricca D Van CittersDilip V Jeste
Dec 18, 2014·Psychogeriatrics : the Official Journal of the Japanese Psychogeriatric Society·Yu-Hsuan WuYu-San Chang
Dec 2, 2004·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Prakash Masand
Jul 18, 2006·Progress in Neuro-psychopharmacology & Biological Psychiatry·Zheng LuQiuqing Ang
Dec 1, 2003·European Psychiatry : the Journal of the Association of European Psychiatrists·Carlo Altamura, Tony Elliott
Jul 14, 2012·The Australian and New Zealand Journal of Psychiatry·Yu-Tao XiangNaotaka Shinfuku
Oct 16, 2003·Pharmacoepidemiology and Drug Safety
Apr 23, 2005·The Cochrane Database of Systematic Reviews·L DugganS Indran
Sep 13, 2005·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·A W AwadallaA M Tawfiq
Dec 24, 2005·Harvard Review of Psychiatry·Dilip V JesteCarl Salzman
Apr 21, 2006·The Cochrane Database of Systematic Reviews·M B JayaramS Stroup
Feb 18, 2012·The Cochrane Database of Systematic Reviews·Adib Essali, Ghassan Ali
Jan 23, 2009·The Cochrane Database of Systematic Reviews·Adib EssaliJohn Rathbone
Apr 6, 2016·The Cochrane Database of Systematic Reviews·Kumar B SahaRashid U Zaman
Dec 24, 2010·Clinical Schizophrenia & Related Psychoses·Kandi FelmetJohn W Kasckow
Aug 2, 2005·The British Journal of Psychiatry : the Journal of Mental Science·Sylvia ParkStephen B Soumerai
Nov 4, 2004·British Journal of Clinical Pharmacology·Rashmi R Shah
Jan 27, 2006·The Cochrane Database of Systematic Reviews·R G MarriottS Waddingham
Aug 15, 2021·Neuropsychopharmacology Reports·UNKNOWN Japanese Society of Neuropsychopharmacology

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Birth Defects

Birth defects encompass structural and functional alterations that occur during embryonic or fetal development and are present since birth. The cause may be genetic, environmental or unknown and can result in physical and/or mental impairment. Here is the latest research on birth defects.